Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selinexor(ATG-010) Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma

NCT05422027 is registered in ClinicalTrials.gov with Xia Zhongjun as lead sponsor.

NCT NCT05422027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05422027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selinexor(ATG-010) Plus Bortezomib, Lenalidomide and Dexamethasone (XVRd) in High Risk Newly Diagnosed Multiple Myeloma
Lead sponsor
Xia Zhongjun
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 25, 2022
Completion date
December 31, 2025
Enrollment
42 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma